Matthew Holtzman, MD
Payments from drug & device makers
Across 4,107 payments — averaging $368.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$586K
- Eisai Inc.$253K
- SK Life Science, Inc.$120K
- Amgen$66K
- Medtronic$62K
- Catalyst Pharmaceuticals, Inc.$51K
- plus $373K from 54 others
Across 10 payments — averaging $168.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Acadia Pharmaceuticals Inc$2K
What the payments were for
- Consulting fees$102,7657%
- Speaking & faculty fees$1,007,24973%
- Travel & lodging$192,26014%
- Food & beverage$67,4255%
- Education$7670%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,512,683 in reported general payments places this provider in the 95th percentile of 652 neurology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 77 | $1,162,309 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 79 | $1,118,109 |
| FirdapseAmifampridine Phosphate | 14 | $739,037 |
| IngrezzaValbenazine Tosylate | 32 | $315,593 |
| NuplazidPimavanserin Tartrate | 49 | $245,819 |
| AptiomEslicarbazepine Acetate | 129 | $214,894 |
| EnspryngSatralizumab-Mwge | 12 | $199,106 |
| FycompaPerampanel | 133 | $159,430 |
| ZeposiaOzanimod Hydrochloride | 13 | $115,106 |
| EpidiolexCannabidiol (Cbd) | 12 | $112,766 |
| CopaxoneGlatiramer Acetate | 12 | $85,368 |
| XcopriCenobamate | 61 | $84,606 |
| UbrelvyUbrogepant | 46 | $76,729 |
| Aimovig AutoinjectorErenumab-Aooe | 90 | $75,646 |
| VraylarCariprazine Hcl | 52 | $73,190 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $513 | $1,118,10979 claims |
| Catalyst Pharmaceuticals, Inc.Firdapse | $51,349 | $739,03714 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $361 | $315,59332 claims |
| Acadia Pharmaceuticals IncNuplazid | $18,424 | $245,81949 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $11,052 | $214,894129 claims |
| AbbVieUbrelvy, Vraylar, Qulipta, Linzess | $585,951 | $212,285163 claims |
| Genentech USA, Inc.Enspryng | $38,973 | $199,10612 claims |
| Eisai Inc.Fycompa | $252,616 | $159,430133 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone, Austedo Xr | $45,620 | $146,43524 claims |
| E.r. Squibb & Sons, L.L.C.Zeposia | $21,444 | $115,10613 claims |
| SK Life Science, Inc.Xcopri | $120,369 | $84,60661 claims |
| Acorda Therapeutics, IncAmpyra | $23,055 | $64,56916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 652 neurology providers in Michigan.
Other neurology in Wayne
- Aaron EllenbogenFarmington Hills$14.5M
- Martin BelkinFarmington Hills$5.8M
- Evanthia BernitsasDetroit$4.8M
- Yang Mao DraayerFarmington Hills$4.2M
- Mirela CerghetDetroit$3.8M
- Peter le WittWest Bloomfield$3.2M
- Judith HeidebrinkAnn Arbor$2.2M
- Denise LeungAnn Arbor$2M
- Rany AburashedOwosso$1.9M
- Jeanie CoteOwosso$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.